

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Tenecteplase for thrombolytic treatment of acute ischaemic stroke ID6306

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Boehringer Ingelheim (tenecteplase) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Arrhythmia Alliance • Blood Pressure UK (formerly Blood Pressure Association) • Brain and Spine Foundation • Brain and Spine Injury Charity (BASIC) • Brain Charity • British Cardiac Patients Association^a • Cardiovascular Care Partnership • Different Strokes • HEART UK • Lifeblood, the Thrombosis Charity • Muslim Council of Great Britain • Myaware • Network of Sikh Organisations • Neurological Alliance • Pumping Marvellous • Sickle Cell and Young Stroke Survivors • South Asian Health Foundation • Specialised Healthcare Alliance • Stroke Association • Stroke Information • Sue Ryder <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association of British Clinical Diabetologists • Association of British Neurologists • British and Irish Hypertension Society • British Association of Stroke Physicians • British Cardiovascular Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • Neurological Alliance of Scotland • NHS Confederation • Scottish Medicines Consortium • Wales Neurological Alliance • Welsh Government • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Boehringer Ingelheim (alteplase) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research UK • British Society for Cardiovascular Research • Cochrane Stroke Group • Cochrane UK • European Council for Cardiovascular Research • Genomics England • MRC Clinical Trials Unit • National Hospital for Neurology and

Provisional stakeholder list for the evaluation of tenecteplase for thrombolytic treatment of acute ischaemic stroke ID6306

Issue date: September 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Dietetic Association • British Geriatrics Society • British Heart Foundation • British and Irish Hypertension Society • British Neuropathological Society • British Society for Haematology • British Society for Haemostasis and Thrombosis • British Society of Cardiovascular Imaging • British Society of Neuroradiologists • Clinical Leaders of Thrombosis (CLOT) • Institute of Neurology • National Neurosciences Advisory Group • Primary Care and Community Neurology Society • Primary Care Diabetes Society • Royal College of Emergency Medicine • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Vascular Nurses • Society of British Neurological Surgeons • The Vascular Society of Great Britain and Ireland • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<p>Neurosurgery</p> <ul style="list-style-type: none"> • National Institute for Health Research • The Society for Research in Rehabilitation • Wellcome Trust <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Provisional stakeholder list for the evaluation of tenecteplase for thrombolytic treatment of acute ischaemic stroke ID6306

Issue date: September 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.

Page 2 of 3

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.